Wall Street analysts’ estimates
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 3Q17. In 3Q17, LLY reported EPS of $1.05 on revenues of ~$5.7 billion compared to its estimated EPS of $1.03 on revenues of ~$5.5 billion. Analysts expect Eli Lilly to report EPS of $1.07 on revenues of ~$5.9 billion during 4Q17.
The chart above compares the changes in analysts’ recommendations for Eli Lilly & Co. over the last 12 months. For fiscal 2017, analysts expect Eli Lilly to report EPS of $4.22 on revenues of ~$22.7 billion, representing 6.7% growth in revenues compared to fiscal 2016.
Eli Lilly’s (LLY) stock price has increased nearly 15.5% in the last 12 months and nearly 3.1% in 2018 year-to-date. Analysts expect its stock to rise 5.8% over the next 12 months.
Wall Street analysts’ recommendations show a 12-month target price of $92.09 per share compared to the last price of $87.08 per share recorded on January 26, 2018.
On January 28, 2018, 24 analysts tracked Eli Lilly & Co. Fourteen of these analysts recommended a “buy,” eight analysts recommended a “hold,” and two analysts recommended a “sell.” The consensus rating for Eli Lilly & Co. stands at ~2.3, which represents a moderate buy for long-term growth investors and value investors.
The iShares US Pharmaceuticals ETF (IHE) holds 5.5% of its total investments in Eli Lilly & Co. (LLY), 6.2% in Bristol-Myers Squibb (BMY), 9.8% in Johnson & Johnson (JNJ), and 7.8% in Merck & Co. (MRK).